Why CMS/AHIP’s prior authorization changes won’t hurt payers.

Myself and Kristy Piccinini, PhD from FTI Consulting published a new commentary in The Evidence Base titled “Perspectives from the Healthcare Economist: Why CMS/AHIP’s prior authorization changes won’t hurt payers.” Dr. Shafrin and Dr. Piccinini share their insights in this Guest Column examining the implications of recent CMS/AHIP prior authorization reforms and why these changes are unlikely…

Read More

We’re Gonna Need a Bigger Boat

By KIM BELLARD My friends, we are like explorers of yore standing at the edge of a known continent, looking out at the vast ocean in hopes of finding new, unspoiled, better lands across it. True, we may have despoiled the continent behind us, but certainly things will be better in the new lands. In…

Read More

World’s Premier Cancer Institute Faces Crippling Cuts and Chaos

The Trump administration’s broadsides against scientific research have caused unprecedented upheaval at the National Cancer Institute, the storied federal government research hub that has spearheaded advances against the disease for decades. NCI, which has long benefited from enthusiastic bipartisan support, now faces an exodus of clinicians, scientists, and other staffers — some fired, others leaving…

Read More

An Arm and a Leg: The Prescription Drug Playbook, Part II

In response to the high price of prescription drugs, “An Arm and a Leg” asked listeners to share their strategies for getting the medicine they need at prices they can manage. Host Dan Weissmann and producers Emily Pisacreta and Claire Davenport share tips from a retired hospital manager who now helps seniors find the right…

Read More